SG11201811506UA - Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof - Google Patents
Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereofInfo
- Publication number
- SG11201811506UA SG11201811506UA SG11201811506UA SG11201811506UA SG11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- preparing
- pct
- precursors
- english
- Prior art date
Links
- 229940126097 immunoproteasome inhibitor Drugs 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- BYPRQOWKWXRIBW-GKAPJAKFSA-N 2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound N1(CCOCC1)CC(=O)N[C@H](C(=O)NC(C(=O)N)C)C BYPRQOWKWXRIBW-GKAPJAKFSA-N 0.000 abstract 1
- 235000001543 Corylus americana Nutrition 0.000 abstract 1
- 240000007582 Corylus avellana Species 0.000 abstract 1
- 235000007466 Corylus avellana Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/02—Synthesis of the oxirane ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356178P | 2016-06-29 | 2016-06-29 | |
| PCT/US2017/039975 WO2018005781A1 (en) | 2016-06-29 | 2017-06-29 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811506UA true SG11201811506UA (en) | 2019-01-30 |
Family
ID=59351085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811506UA SG11201811506UA (en) | 2016-06-29 | 2017-06-29 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10781192B2 (es) |
| EP (2) | EP4296257A3 (es) |
| JP (2) | JP7065044B2 (es) |
| KR (2) | KR102571568B1 (es) |
| AR (1) | AR108919A1 (es) |
| AU (1) | AU2017290147B2 (es) |
| BR (1) | BR112018077250A2 (es) |
| CA (1) | CA3029418A1 (es) |
| CL (1) | CL2018003873A1 (es) |
| CO (1) | CO2019000866A2 (es) |
| EA (1) | EA201990157A1 (es) |
| IL (2) | IL302234A (es) |
| MX (1) | MX2018016386A (es) |
| SG (1) | SG11201811506UA (es) |
| TW (1) | TWI751177B (es) |
| WO (1) | WO2018005781A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018016386A (es) * | 2016-06-29 | 2019-09-09 | Kezar Life Sciences | Proceso de preparacion de un inhibidor de inmunoproteasoma de peptido epoxicetona, y precursores del mismo. |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| CA2504933C (en) | 2002-11-06 | 2012-10-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
| EP1948678B1 (en) | 2005-11-09 | 2013-05-01 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| AU2007261345B2 (en) | 2006-06-19 | 2012-02-23 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| MX2010003732A (es) | 2007-10-04 | 2010-08-09 | Onyx Therapeutics Inc | Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido. |
| CN101525370A (zh) * | 2008-03-06 | 2009-09-09 | 海南建邦制药科技有限公司 | 一种新型高效多肽合成缩合剂 |
| MX2011004225A (es) | 2008-10-21 | 2011-06-21 | Onyx Therapeutics Inc | Terapia de combinacion con epoxicetonas peptidicas. |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
| KR20130094185A (ko) | 2010-04-07 | 2013-08-23 | 오닉스 세라퓨틱스, 인크. | 결정성 펩티드 에폭시케톤 면역프로테아좀 저해제 |
| US8609610B2 (en) | 2011-02-18 | 2013-12-17 | Trustees Of Dartmouth College | Inhibitors of the trypsin-like site of the proteasome and methods of use thereof |
| EP2705027B1 (en) | 2011-05-02 | 2015-06-03 | Gilead Sciences, Inc. | Amorphous solid salts of Cobicistat (GS-9350) |
| CA2873044C (en) | 2012-05-08 | 2021-01-26 | Onyx Therapeutics, Inc. | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
| US9187442B2 (en) | 2012-06-29 | 2015-11-17 | Nissan Chemical Industies, Ltd. | Method for producing stereoselective epoxyketone compound |
| CN104837858A (zh) | 2012-10-11 | 2015-08-12 | 弗·哈夫曼-拉罗切有限公司 | 酮酰胺免疫蛋白酶体抑制剂 |
| RU2015117581A (ru) | 2012-10-12 | 2016-12-10 | Ф. Хоффманн-Ля Рош Аг | Макроциклические кетоамидные ингибиторы иммунопротеасом |
| UY35091A (es) * | 2012-10-24 | 2014-05-30 | Onyx Therapeutics Inc | Formulaciones de liberacion modificada para oprozomib |
| KR102365509B1 (ko) * | 2013-03-14 | 2022-02-21 | 오닉스 세라퓨틱스, 인크. | 트리펩타이드 에폭시 케톤 프로테이스 억제제 |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| US9657057B2 (en) * | 2013-03-14 | 2017-05-23 | Onyx Therapeutics, Inc. | Dipeptide and tripeptide epoxy ketone protease inhibitors |
| CN104710507B (zh) * | 2013-12-11 | 2018-08-14 | 深圳翰宇药业股份有限公司 | 一种卡非佐米的制备方法 |
| CN104230857A (zh) | 2014-08-19 | 2014-12-24 | 上海皓元生物医药科技有限公司 | 卡非佐米(Carfilzomib)的中间体化合物的制备方法及其中间体化合物 |
| MX2018016386A (es) * | 2016-06-29 | 2019-09-09 | Kezar Life Sciences | Proceso de preparacion de un inhibidor de inmunoproteasoma de peptido epoxicetona, y precursores del mismo. |
-
2017
- 2017-06-29 MX MX2018016386A patent/MX2018016386A/es unknown
- 2017-06-29 EP EP23191555.4A patent/EP4296257A3/en active Pending
- 2017-06-29 CA CA3029418A patent/CA3029418A1/en active Pending
- 2017-06-29 KR KR1020237013160A patent/KR102571568B1/ko active IP Right Grant
- 2017-06-29 SG SG11201811506UA patent/SG11201811506UA/en unknown
- 2017-06-29 EA EA201990157A patent/EA201990157A1/ru unknown
- 2017-06-29 AU AU2017290147A patent/AU2017290147B2/en active Active
- 2017-06-29 KR KR1020197002872A patent/KR102524751B1/ko active IP Right Grant
- 2017-06-29 AR ARP170101808A patent/AR108919A1/es unknown
- 2017-06-29 TW TW106121701A patent/TWI751177B/zh active
- 2017-06-29 WO PCT/US2017/039975 patent/WO2018005781A1/en unknown
- 2017-06-29 US US16/312,688 patent/US10781192B2/en active Active
- 2017-06-29 JP JP2018568194A patent/JP7065044B2/ja active Active
- 2017-06-29 IL IL302234A patent/IL302234A/en unknown
- 2017-06-29 EP EP17740180.9A patent/EP3478669B1/en active Active
- 2017-06-29 BR BR112018077250-0A patent/BR112018077250A2/pt unknown
- 2017-06-29 IL IL263771A patent/IL263771B2/en unknown
-
2018
- 2018-12-28 CL CL2018003873A patent/CL2018003873A1/es unknown
-
2019
- 2019-01-29 CO CONC2019/0000866A patent/CO2019000866A2/es unknown
-
2020
- 2020-09-09 US US17/015,450 patent/US11498907B2/en active Active
-
2022
- 2022-04-25 JP JP2022071492A patent/JP7392031B2/ja active Active
- 2022-10-13 US US17/965,064 patent/US11976053B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201807012QA (en) | Acid addition salts of piperazine derivatives | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201901959YA (en) | Modified stem cell memory t cells, methods of making and methods of using same | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201806639VA (en) | New streptococcal proteases | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |